TY - JOUR T1 - PET of α<sub>v</sub>β<sub>3</sub>-Integrin and α<sub>v</sub>β<sub>5</sub>-Integrin Expression with <sup>18</sup>F-Fluciclatide for Assessment of Response to Targeted Therapy: Ready for Prime Time? JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 335 LP - 337 DO - 10.2967/jnumed.110.078568 VL - 52 IS - 3 AU - Ambros J. Beer AU - Markus Schwaiger Y1 - 2011/03/01 UR - http://jnm.snmjournals.org/content/52/3/335.abstract N2 - ER -